趾甲甲真菌病单药治疗:系统评价与网络荟萃分析
该网络荟萃分析纳入26项随机对照试验共8136例患者,比较口服与外用单药治疗趾甲甲真菌病的疗效与安全性。结果显示连续特比萘芬250 mg或连续伊曲康唑200 mg的真菌学治愈 odds 显著高于外用治疗,而氟康唑、脉冲方案与外用治疗间无显著差异;各治疗不良事件 odds 无显著差异。
要点
- 连续特比萘芬250 mg或连续伊曲康唑200 mg的真菌学治愈 odds 显著优于外用治疗。
- 氟康唑、特比萘芬或伊曲康唑脉冲方案与外用治疗的真菌学治愈 odds 无显著差异。
- 口服与外用治疗的不良事件 odds 无显著差异,证据质量因结局而异。
核心结论
- 口服和外用单药治疗趾甲甲真菌病在实现真菌学治愈方面安全有效。
- 连续特比萘芬250 mg或连续伊曲康唑200 mg的真菌学治愈 odds 显著高于外用治疗。
研究设计与样本
- 系统评价与随机效应网络荟萃分析,遵循Cochrane规则和GRADE方法评估证据质量。
- 共77项随机对照试验,其中26项纳入合并 odds 比分析,共8136例患者。
- 因符合条件的联合治疗和器械治疗试验不足,未纳入网络荟萃分析。
主要发现
- 直接与间接证据间无显著不一致性。
- 连续特比萘芬250 mg或连续伊曲康唑200 mg的真菌学治愈 odds 显著高于外用治疗。
- 氟康唑、特比萘芬和伊曲康唑的脉冲方案以及外用治疗之间真菌学治愈 odds 无显著差异。
- 口服或外用治疗的不良事件 odds 相互间无显著差异。
- 真菌学治愈的证据质量为中或高,不良事件的证据质量从极低到高不等。
关键数值与推荐
- 连续特比萘芬250 mg或连续伊曲康唑200 mg的真菌学治愈 odds 显著高于外用治疗。
- 氟康唑、脉冲方案与外用治疗的真菌学治愈 odds 无显著差异。
- 口服与外用治疗的不良事件 odds 无显著差异。
临床怎么用
- 趾甲甲真菌病单药治疗可优先考虑连续特比萘芬250 mg或连续伊曲康唑200 mg以获得更高的真菌学治愈 odds。
- 口服与外用治疗不良事件风险无显著差异,选择时需综合疗效与患者个体情况。
局限性
- 符合条件的联合治疗和器械治疗试验不足,未能纳入网络荟萃分析。
- 不良事件证据质量从极低到高不等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Onychomycosis is a fungal infection of the nail caused by dermatophytes, yeasts and nondermatophyte moulds that accounts for approximately 50% of all nail-related disease. OBJECTIVES: This study aims to assess the effectiveness and safety of monotherapy and combination treatments for toenail onychomycosis using a network meta-analysis (NMA). METHODS: Quality of evidence was assessed using Cochrane-compliant rules and the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Efficacy and safety outcomes were compared using a random-effects NMA to estimate pooled odds ratios (ORs) of direct and indirect comparisons among oral and topical treatments (PROSPERO 2015: CRD42018086912). There were not enough eligible combination and device-based therapy trials to include in the NMA. RESULTS: Of 77 randomized controlled trials, 26 were included in the ORs (8136 patients). There were no significant inconsistencies between the direct and indirect evidence. Relative effects show that the odds of mycological cure with continuous terbinafine 250 mg or continuous itraconazole 200 mg are significantly greater than topical treatments. Fluconazole, pulse regimens of terbinafine and itraconazole, and topical treatments did not differ significantly in the odds of achieving mycological cure. The ORs of adverse events occurring with oral or topical treatments were not significantly different from each other. For mycological cure, evidence was of moderate or high quality while evidence ranged from very low to high quality for adverse events. CONCLUSIONS: Our review suggests that oral and topical treatments for toenail onychomycosis are safe and effective in producing mycological cure. What's already known about this topic? Topical treatments traditionally have lower success rates than oral treatments. Oral treatments have the advantage of shorter treatment durations, but also present challenges in cases of drug-drug interactions or immunosuppression. A network meta-analysis (NMA) gathers data from indirect evidence to gain confidence about all treatment comparisons and allows for estimation of comparative effects that have not been investigated in head-to-head randomized clinical trials (RCTs). What does this study add? This NMA of efficacy and safety includes all RCTs of oral, topical, combination and device-based treatments for toenail onychomycosis, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for NMA. The odds of achieving mycological cure with continuous terbinafine 250 mg or continuous itraconazole 200 mg were significantly greater than topical treatments. Fluconazole, pulse regimens of terbinafine and itraconazole, and topical treatments did not differ significantly in the odds of achieving mycological cure.
引用
- Gupta AK, Foley KA, Mays RR, et al. Monotherapy for toenail onychomycosis: a systematic review and network meta-analysis. Br J Dermatol. 2019. PMID: 31120134. doi:10.1111/bjd.18155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。